J. Safra Sarasin Holding AG Sells 141,012 Shares of Medtronic PLC $MDT

J. Safra Sarasin Holding AG cut its position in Medtronic PLC (NYSE:MDT) by 81.8% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 31,313 shares of the medical technology company’s stock after selling 141,012 shares during the period. J. Safra Sarasin Holding AG’s holdings in Medtronic were worth $2,724,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MDT. 1248 Management LLC bought a new position in shares of Medtronic in the 1st quarter valued at about $26,000. Burkett Financial Services LLC lifted its position in shares of Medtronic by 185.0% in the first quarter. Burkett Financial Services LLC now owns 285 shares of the medical technology company’s stock valued at $26,000 after buying an additional 185 shares during the last quarter. Columbia River Financial Group LLC acquired a new position in shares of Medtronic during the 1st quarter worth approximately $28,000. Twin Tree Management LP bought a new stake in Medtronic in the 1st quarter valued at $29,000. Finally, Activest Wealth Management raised its stake in Medtronic by 3,577.8% in the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock valued at $30,000 after acquiring an additional 322 shares during the period. 82.06% of the stock is owned by institutional investors.

Medtronic Stock Performance

Shares of NYSE:MDT opened at $95.57 on Friday. Medtronic PLC has a 1 year low of $79.29 and a 1 year high of $96.25. The stock has a market capitalization of $122.59 billion, a price-to-earnings ratio of 26.33, a price-to-earnings-growth ratio of 2.50 and a beta of 0.78. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50. The company’s 50 day simple moving average is $92.85 and its 200 day simple moving average is $88.46.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.03. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The firm had revenue of $8.58 billion for the quarter, compared to the consensus estimate of $8.37 billion. During the same quarter last year, the business posted $1.23 EPS. The company’s revenue was up 7.7% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. As a group, research analysts predict that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 17th. Shareholders of record on Friday, September 26th will be paid a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $2.84 annualized dividend and a yield of 3.0%. Medtronic’s payout ratio is presently 78.24%.

Insider Activity

In related news, EVP Harry Skip Kiil sold 8,605 shares of the company’s stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total transaction of $788,045.90. Following the completion of the transaction, the executive vice president directly owned 35,615 shares in the company, valued at $3,261,621.70. This represents a 19.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William R. Jellison bought 2,500 shares of the business’s stock in a transaction on Monday, August 25th. The stock was bought at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the transaction, the director directly owned 5,000 shares of the company’s stock, valued at approximately $461,850. This represents a 100.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.26% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on MDT shares. Wolfe Research raised shares of Medtronic from an “underperform” rating to a “peer perform” rating in a research report on Monday, June 30th. Argus raised their price objective on shares of Medtronic from $105.00 to $115.00 and gave the stock a “buy” rating in a research report on Tuesday, August 26th. Needham & Company LLC restated a “hold” rating on shares of Medtronic in a report on Thursday, August 14th. BTIG Research reiterated a “neutral” rating on shares of Medtronic in a research note on Friday, July 11th. Finally, Wells Fargo & Company upped their price objective on Medtronic from $98.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $102.27.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.